Other languages Profound Medical Corp.

Equities

PRN

CA74319B5027

Market Closed - Toronto S.E. Other stock markets 01:29:59 07/05/2024 am IST			5-day change	1st Jan Change
10.04 ^CAD	-0.20%		-4.38%	-9.55%

13/03	Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
11/03	Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	08/03
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers	27/02
Profound Medical Up 1.9% In US After Hours As Announces Non-Brokered Private Placement	17/01
Sector Update: Health Care Stocks Steady Premarket Thursday	28/12
Wall Street in Consolidation Mode in Penultimate Session for 2023, Driving Muted Premarket Action for US Equity Futures	28/12
Profound Medical Prices $20 Million Public Share Offering	28/12
Profound Medical Plans Stock Offering; Shares Drop After-Hours	28/12
Profound Medical Announces CMS Extension of Temporary 'Code' for Tulsa to ASC Setting	03/11
Profound Medical Corp. Announces CMD Extension of Temporary Code for TULSA to ASC Setting	03/11
Profound Medical Reports Q3 2023 Revenue of US$1.7 Million	03/11
Profound Medical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Profound Medical Gets FDA Clearance for Tulsa-Pro Thermal Boost	26/23/26
Profound Medical Corp. Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost	26/23/26
Profound Medical Plans At-the-Market Offering of up to US$30 Million; Up Nearly 5%	07/23/07
Profound Medical Approves At-the-Market Offering of Up to $30 Million of Common Stock	07/23/07
Profound Medical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
Profound Medical Reports Q2 Net Loss of US$7.4 Million	10/23/10
Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases	02/23/02
Profound Medical Reports Q1 2023 Results, Provides Operations Update	11/23/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Profound Medical Corp.

Equities

PRN

CA74319B5027

Other languages

Filters